intellectual property protection | Institut Fraser

Who was Barbara Mitchell?

Janvier 30, 2017 4:46PM

Canada’s inadequate intellectual property rights protections hurt patients and the economy

Kristina M.L. Acri, née Lybecker

There are numerous deficiencies that weaken intellectual property protections within Canada relative to other industrialized countries.

Étiquettes:

intellectual property rights, intellectual property for pharmaceuticals, intellectual property protection, pharmaceutical innovation, biologics, pharmaceutical manufacture

Janvier 24, 2017 1:00AM

Intellectual Property Rights Protection and the Biopharmaceutical Industry: How Canada Measures Up

Kristina M.L. Acri, née Lybecker

Intellectual Property Rights Protection and the Biopharmaceutical Industry: How Canada Measures Up

Étiquettes:

intellectual property rights, intellectual property for pharmaceuticals, intellectual property protection, pharmaceutical innovation, biologics, pharmaceutical manufacture

Octobre 14, 2016 1:30AM

Intellectual Property Rights and the Promotion of Biologics, Medical Devices, and Trade in Pharmaceuticals

Steven Globerman, Kristina M.L. Acri, née Lybecker, Christopher Sands, Tomas J. Philipson

Intellectual Property Rights and the Promotion of Biologics, Medical Devices, and Trade in Pharmaceuticals

Étiquettes:

intellectual property rights, intellectual property for pharmaceuticals, intellectual property protection, pharmaceutical innovation, biologics, pharmaceutical manufacture

Juillet 9, 2013 2:00AM

Trade and Economic Benefits of Enhanced Intellectual Property Protection for Pharmaceuticals in Canada

Nadeem Esmail, Kristina M.L. Acri, née Lybecker, Laura Dawson

Étiquettes:

intellectual property, pharmaceuticals, intellectual property protection, CETA, pharmaceutical innovation, ip protection, trans-pacific partnership, TPP, trade benefits, economic benefits